Last reviewed · How we verify
Dexamethasone + Ondansetron
Dexamethasone suppresses inflammation and immune responses via glucocorticoid receptor activation, while ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting.
Dexamethasone suppresses inflammation and immune responses via glucocorticoid receptor activation, while ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) with anti-inflammatory support, Post-operative nausea and vomiting (PONV) with inflammatory management.
At a glance
| Generic name | Dexamethasone + Ondansetron |
|---|---|
| Sponsor | University of Catania |
| Drug class | Corticosteroid + 5-HT3 antagonist combination |
| Target | Glucocorticoid receptor; 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; General Surgery; Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone is a potent corticosteroid that reduces inflammation by inhibiting phospholipase A2 and suppressing cytokine production. Ondansetron is a selective 5-HT3 antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. This combination is used to manage both inflammatory conditions and chemotherapy-induced or post-operative nausea and vomiting.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) with anti-inflammatory support
- Post-operative nausea and vomiting (PONV) with inflammatory management
Common side effects
- Headache
- Constipation
- Hyperglycemia
- Insomnia
- Immunosuppression
Key clinical trials
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Dexamethasone vs Ondansetron After Cesarean Delivery (PHASE4)
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients (PHASE2)
- Thoracic Epidural Analgesia With Bilateral Erector Spinae Plane Block in Radical Cystectomy Surgery (NA)
- A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC (PHASE3)
- Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis (NA)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone + Ondansetron CI brief — competitive landscape report
- Dexamethasone + Ondansetron updates RSS · CI watch RSS
- University of Catania portfolio CI